Lab-in-the-Loop at Compute Speed — Ian Quigley, Leash Bio

Leash Bio shows small-molecule drug discovery AI still fails on genuinely novel chemistry, but physically-grounded, artifact-aware data collection may close that gap.

• DEL scale: Leash has screened ~2,000 protein constructs, ~5,000 screens, over 6.5M molecules each, costing far less than CRO rates (~$100k per one-off screen).
• Kaggle shock: A 2022-ish contest with ~2,000 teams and 4B+ measurements found nobody beat chance on an unseen chemical library, validating Leash's scaling bet.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.